Every material Form 8-K UnitedHealth has filed with the SEC since November 07, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
UnitedHealth Group reported third quarter 2026 diluted earnings of $4.56 per share, up from $2.59 a year earlier, on revenues of $112.7 billion, down slightly from $113.2 billion. The company raised its full-year 2026 outlook to at least $20.50 per share in adjusted earnings, which matters to shareholders because profit rose while the outlook improved.
Diluted EPS was $4.56 versus $2.59 in Q3 2025; adjusted EPS was $4.69 versus $2.92.
Earnings from operations were $6.6 billion versus $4.3 billion; revenues were $112.7 billion versus $113.2 billion.
Full-year 2026 outlook: at least $19.50 per share in diluted earnings and at least $20.50 per share in adjusted earnings.
Medical care ratio was 88.4% versus 89.9% a year earlier; debt-to-capital ratio was 41.7% as of September 30, 2026.
UnitedHealth Group announced that senior leaders will take part in an interview-format discussion at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, starting at 8:00 a.m. Eastern Time. The discussion will cover strategy, market positions, recent results and expectations for its end markets, and a live audio webcast will be available on the company's Investor Relations page.
Presentation at Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, beginning 8:00 a.m. Eastern Time
Topics include strategy, market positions, recent results and expectations for end markets
Live audio webcast available through the Investor Relations page at www.unitedhealthgroup.com
UnitedHealth Group reported second quarter 2026 revenue of $112.0 billion, up from $111.6 billion a year earlier, and diluted earnings of $6.04 per share, up from $3.74. The company raised its full-year 2026 adjusted earnings outlook to $19.50 to $20.00 per share from $17.75 as of January 27, 2026, which signals higher expected profit for shareholders.
Q2 2026 earnings from operations were $8.0 billion, compared with $5.2 billion in Q2 2025.
Diluted EPS was $6.04 versus $3.74 a year earlier; adjusted EPS was $6.38 versus $4.08.
Full-year 2026 adjusted EPS outlook raised to $19.50 to $20.00; diluted EPS outlook set at $18.45 to $18.95.
Medical care ratio was 86.7% versus 89.4% in Q2 2025; the company has repurchased $4.0 billion of stock through mid-July 2026 and expects at least $5.0 billion for the year.
UnitedHealth Group's senior leaders will take part in an interview-format discussion at the Bank of America Securities Health Care Conference 2026 on May 12, 2026, starting at 11:00 a.m. Eastern Time. The filing says topics may include strategy, market positions, recent results and expectations for its end markets, and a live audio webcast will be posted on the company's Investor Relations page. The filing contains no new financial figures, so it is an administrative notice rather than a results or guidance update.
Event: Bank of America Securities Health Care Conference 2026, interview format
Date and time: Tuesday, May 12, 2026, beginning 11:00 a.m. Eastern Time
Live audio webcast available through the Investor Relations page at www.unitedhealthgroup.com
Filing contains no new financial results or guidance figures
UnitedHealth reported first quarter 2026 revenue of $111.7 billion, up from $109.6 billion a year earlier, and GAAP earnings of $6.90 per share, up from $6.85. The company raised its full-year 2026 earnings outlook to greater than $17.35 per share on a GAAP basis and greater than $18.25 per share on an adjusted basis. Earnings from operations were $9.0 billion, slightly below $9.1 billion a year earlier.
Q1 2026 revenue was $111.7 billion, up from $109.6 billion in Q1 2025; GAAP EPS was $6.90 versus $6.85, and adjusted EPS was $7.23 versus $7.20.
Full-year 2026 outlook raised to greater than $17.35 per share GAAP and greater than $18.25 per share adjusted.
Medical care ratio improved to 83.9% from 84.8%, while the operating cost ratio rose to 13.8% from 12.4%.
The company expects to repurchase at least $2.0 billion of its common stock by the end of the second quarter 2026 and has agreed to acquire Alegeus Technologies.
UnitedHealth Group said senior leaders will take part in an interview-format discussion at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, starting at 11:30 a.m. Eastern Time. The filing says the talk will cover strategy, market positions, recent results and expectations for its end markets, and a live audio webcast will be available on the company's Investor Relations page.
Presentation date and time: Tuesday, March 10, 2026, beginning at 11:30 a.m. Eastern Time
Event: Barclays 28th Annual Global Healthcare Conference
Topics include strategy, market positions, recent results and expectations for end markets
Live audio webcast available through the Investor Relations page at www.unitedhealthgroup.com
UnitedHealth Group appointed Dennis Stankiewicz, its Corporate Controller, as Chief Accounting Officer effective March 2, 2026. Tom Roos, CAO since August 2015, moves to become CFO of Optum Insight on the same date.
Dennis Stankiewicz, 48, appointed Chief Accounting Officer effective March 2, 2026; he will also remain Corporate Controller, a role held since April 17, 2023
Stankiewicz joined the company in August 2016 as General Auditor and previously was a partner at Deloitte & Touche, LLP
Stankiewicz's pay includes a $550,000 annual base salary, an initial cash bonus target of 85% of base salary, and severance equal to one times base salary
Tom Roos, CAO since August 2015, becomes CFO of Optum Insight effective March 2, 2026
UnitedHealth's Compensation and Human Resources Committee amended a stock option granted to CEO Stephen Hemsley on May 14, 2025. The amendment adds a requirement that Hemsley hold net shares acquired on exercise until May 14, 2030, except in cases of death or disability. The filing says all other terms of the option are unchanged, so the change mainly affects how long the executive must keep shares he receives from the option.
Committee amended the stock option granted to Stephen Hemsley on May 14, 2025, on February 23, 2026
Amendment adds a two-year share holding requirement after a three-year cliff vesting
Hemsley must hold net shares from exercise until May 14, 2030, except in death or disability
UnitedHealth reported fourth quarter and full year 2025 results on January 27, 2026. Full year revenue rose to $447.6 billion, but diluted earnings per share fell to $13.23 from $15.51, after a fourth quarter charge of $1.6 billion net of taxes, or $1.78 per share. The company also issued 2026 guidance calling for diluted earnings per share above $17.10 and adjusted earnings per share above $17.75.
Q4 2025 diluted EPS was $0.01 versus $5.98 in Q4 2024; adjusted EPS was $2.11 versus $6.81
Full year 2025 revenue was $447.6 billion, up 12% year over year; diluted EPS was $13.23 versus $15.51 in 2024
Q4 2025 included a $1.6 billion net-of-tax charge ($1.78 per share) tied to cyberattack costs, divestitures, and restructuring
2026 outlook: revenue above $439.0 billion, earnings from operations above $24.0 billion, and cash flows from operations above $18.0 billion
UnitedHealth said senior management will meet with investors on January 12, 2026 and intends to reaffirm the adjusted 2025 earnings per share expectations it gave on October 28, 2025. The company also warned that full-year 2025 financial closing procedures are not complete, so actual results could change and fall outside the previously disclosed ranges.
Senior management meetings with investors on January 12, 2026
Intent to reaffirm adjusted 2025 EPS expectations first disclosed October 28, 2025
Full-year 2025 closing procedures not yet complete; results could fall outside the ranges
UnitedHealth Group named Scott Gottlieb, M.D., a former FDA commissioner, as an independent director effective immediately, as announced November 18, 2025. He has not yet been assigned to any board committees. The filing describes standard director compensation and indemnification arrangements, and no financial results or guidance were reported.
Scott Gottlieb, M.D. appointed independent director, effective immediately, announced November 18, 2025
Gottlieb has not yet been appointed to any board committees
He served as FDA commissioner from 2017 to 2019 and also serves as a director of Pfizer, Tempus AI and Illumina
Compensation follows the company's standard non-employee director program; he is entering the standard indemnification agreement
UnitedHealth Group said senior leaders will take part in an interview-format discussion at the UBS Global Healthcare Conference 2025 on Monday, November 10, 2025, starting at 8:45 a.m. Eastern Time. The discussion will cover strategy, market positions, recent results and expectations for its end markets, and a live audio webcast will be posted on the company's Investor Relations page. The filing contains no new financial figures, so it adds no new earnings or guidance information for shareholders.
Presentation at UBS Global Healthcare Conference 2025 on Monday, November 10, 2025, beginning 8:45 a.m. Eastern Time
Topics include strategy, market positions, recent results and expectations for end markets
Live audio webcast available through the Investor Relations page at www.unitedhealthgroup.com
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every UnitedHealth filing is on SEC EDGAR ↗. 8-K briefs of other companies →